Compare CVLG & AGMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVLG | AGMB |
|---|---|---|
| Founded | 1986 | 2017 |
| Country | United States | Belgium |
| Employees | N/A | 62 |
| Industry | Trucking Freight/Courier Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 634.1M | 562.4M |
| IPO Year | 1996 | N/A |
| Metric | CVLG | AGMB |
|---|---|---|
| Price | $37.43 | $11.34 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $32.00 |
| AVG Volume (30 Days) | ★ 176.7K | 64.9K |
| Earning Date | 04-23-2026 | 04-23-2026 |
| Dividend Yield | ★ 0.80% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $705,007,000.00 | N/A |
| Revenue This Year | $7.17 | N/A |
| Revenue Next Year | $7.53 | $17.86 |
| P/E Ratio | $218.88 | ★ N/A |
| Revenue Growth | ★ 5.12 | N/A |
| 52 Week Low | $18.00 | $9.00 |
| 52 Week High | $37.21 | $17.45 |
| Indicator | CVLG | AGMB |
|---|---|---|
| Relative Strength Index (RSI) | 73.72 | 51.68 |
| Support Level | $31.09 | $9.62 |
| Resistance Level | N/A | $12.29 |
| Average True Range (ATR) | 1.36 | 0.93 |
| MACD | 0.30 | -0.02 |
| Stochastic Oscillator | 92.30 | 36.97 |
Covenant Logistics Group Inc together with its wholly-owned subsidiaries, offers truckload transportation and freight brokerage services to customers throughout the continental United States. The company's reportable segments include Expedited, Dedicated Services, Managed Freight, and Warehousing. The expedited segment provides truckload services to customers with high service freight and delivery standards. Dedicated segment provides customers with committed truckload capacity over contracted periods with the goal of three to five years in length. The Managed Freight segment includes brokerage services and TMS. The warehousing segment provides day-to-day warehouse management services to customers who have chosen to outsource this function.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.